evolocumab

Brand: Repatha

Prototype Drug
Drug Class: PCSK9 inhibitor
Drug Family: antilipemic
Subclass: fully human monoclonal antibody (IgG2)
Organ Systems: cardiovascular

Mechanism of Action

Inhibits PCSK9, preventing its binding to and degradation of LDL receptors; LDL receptors remain on hepatocyte surface for continued LDL clearance; up to 60% additional LDL reduction on top of maximal statin therapy.

PCSK9 (proprotein convertase subtilisin/kexin type 9)

Indications

  • ASCVD (secondary prevention)
  • heterozygous or homozygous familial hypercholesterolemia
  • primary hyperlipidemia uncontrolled on statins

Contraindications

  • latex allergy (prefilled autoinjector)

Adverse Effects

Common

  • injection site reactions
  • nasopharyngitis
  • back pain
  • flu-like symptoms

Serious

  • neurocognitive events (rare, causality uncertain)
  • antibody development (rare)

Pharmacokinetics (ADME)

Absorption 72% SC bioavailability
Distribution moderate
Metabolism proteolytic degradation/target-mediated
Excretion degradation
Half-life ~11-17 days (SC injection)
Onset 7 days (SC)
Peak 3-4 days
Duration 2-4 weeks
Protein Binding <0%
Vd SC distribution

Drug Interactions

Drug / Agent Mechanism Severity
statins additive LDL reduction (beneficial) beneficial

Nursing Considerations

  1. SC injection q2 weeks or monthly (1 ml) — teach auto-injector technique
  2. FOURIER trial: 15% reduction in CV events (MI, stroke) vs placebo on background statin therapy
  3. Store in refrigerator (2-8°C); may be kept at room temp up to 30 days
  4. Common cold symptoms in first weeks — usually self-limited
  5. Insurance prior authorization often required due to cost (~$14,000/year)

Clinical Pearls

  • FOURIER: evolocumab 140 mg q2w reduced MI 27% and stroke 21% over 2.2 years on background statin
  • LDL reduction of 59% — most potent LDL-lowering agent available
  • Biologic mechanism: PCSK9 naturally promotes LDL receptor degradation; inhibition prevents this

Safety Profile

Pregnancy avoid
Lactation insufficient-data
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.